ARCUTIS BIOTHERAPEUTIC

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

19 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 سبتمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

28 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

22 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14 أغسطس 2024 21:00:03 بحسب Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14 أغسطس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 أغسطس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

01 أغسطس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

29 يوليو 2024 07:35:00 بحسب Nasdaq GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

29 يوليو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

23 يوليو 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

22 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

09 يوليو 2024 16:53:01 بحسب Nasdaq GlobeNewswire

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

09 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 يوليو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

10 يونيو 2024 14:30:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 يونيو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

03 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

14 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire